Search results for "Heart Failure"

showing 10 items of 863 documents

Role of ARBs in the blood hypertension therapy and prevention of cardiovascular events

2009

Hypertension has a worldwide high incidence in the general population and undoubtedly it is the most important risk factor for cardiovascular morbidity and mortality, in industrialized countries. In this Review we investigated the role of angiotensin II receptor antagonists (ARBs) therapy in the treatment of essential hypertension. We selected in the PubMed and in a list of selected sources the most significant clinical trials and meta-analysis carried out from 1999 to now, to assess, in adult patients populations, ARBs efficacy, safety and tolerability profile, in comparison with the efficacy of the other common antihypertensive drugs, with particular regard to both the prevention of disab…

Angiotensin receptormedicine.medical_specialtyHeart DiseasesCost-Benefit AnalysisClinical BiochemistryPopulationPeptidyl-Dipeptidase AEssential hypertensionAngiotensin Receptor AntagonistsInternal medicineDrug DiscoverymedicineHumansRisk factoreducationAntihypertensive AgentsPharmacologyeducation.field_of_studyClinical Trials as TopicAngiotensin Receptor Antagonistsbusiness.industrymedicine.diseaseClinical trialCerebrovascular DisordersTreatment OutcomeTolerabilityARB blood hypertension cardiovascular eventsHeart failureHypertensionCardiologyMolecular Medicinebusiness
researchProduct

Arterial hypertension in cancer: The elephant in the room

2019

The great therapeutical success achieved by oncology is counterbalanced by growing evidences of cardiovascular (CV) toxicity due to many antineoplastic treatments. Cardiac adverse events may cause premature discontinuation of effective oncologic treatments or occur as late events undermining the oncologic success. Arterial hypertension is both the most common comorbidity in cancer patients and a frequent adverse effect of anticancer therapies. A pre-existing hypertension is known to increase the risk of other cardiac adverse events due to oncologic treatments, in particular heart failure. Moreover, as a strict association between cancer and CV diseases has emerged over the recent years, var…

Arterial hypertensionVascular Endothelial Growth Factor AAnthracyclines Anti VEGF agents Anti-hypertensive therapy Arterial hypertension Cancer Cardiotoxicitymedicine.medical_specialtyAnti VEGF agentmedicine.medical_treatmentAntineoplastic AgentsBlood PressureAnthracycline030204 cardiovascular system & hematologyAnthracyclines; Anti VEGF agents; Anti-hypertensive therapy; Arterial hypertension; Cancer; Cardiotoxicity; Antihypertensive Agents; Antineoplastic Agents; Blood Pressure; Humans; Hypertension; Neoplasms; Vascular Endothelial Growth Factor A03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansAnthracyclines030212 general & internal medicineAnti-hypertensive therapyAdverse effectIntensive care medicineAntihypertensive AgentsCancerChemotherapyCardiotoxicitybusiness.industryAnti VEGF agentsCancermedicine.diseaseComorbidityCardiotoxicityDiscontinuationBlood pressureHeart failureHypertensionCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

A refugee newborn with heart failure and initial hydrops: Diagnostic clues of spectral Doppler examinations

2022

A newnborn admitted to NICU showed a severe clinical profile

Artero venous malformationmedicine.medical_specialtybusiness.industryRefugeeSpectral dopplerGestational ageGestational agemedicine.diseaserefugee bonesdoppler echographyInternal medicineHeart failurePediatrics Perinatology and Child HealthCardiologymedicinebusinessJournal of Paediatrics and Child Health
researchProduct

Selective pacing sites

2015

The right ventricular apex (RVA) has always been the most used pacing site, because it is easily accessible and provides a stable lead position with a low dislodgment rate. However, it is well-known that long-term right ventricular apical pacing may have deleterious effects on left ventricular function by inducing a iatrogenic left bundle branch block, which can have strong influences on the left ventricle hemodynamic performances. More specifically, RVA pacing causes abnormal contraction patterns and the consequent dyssynchrony may cause myocardial perfusion defects, histopathological alterations, left ventricular dilation and both systolic and diastolic left ventricular dysfunction. All t…

ArtificialHeart failureCardiac pacingCardiology and Cardiovascular MedicineHeart ventricle
researchProduct

Neurogenic pulmonary oedema after generalized epileptic seizure

1998

The diagnosis 'tonic clonic seizure' is frequently established by emergency physicians on scene. In patients with epilepsy mortality due to accidents, asphyxia, cardiac arrhythmias or postictal neurogenic pulmonary oedema (NPO) is twice as high as in the general population. We report a case of acute pulmonary oedema after a tonic clonic seizure. Following this event, the patient developed respiratory insufficiency and evidence of pulmonary oedema not associated with the classic aetiologies of congestive heart failure, aspiration or toxic exposure. The patient survived the incident after aggressive prehospital treatment, long-term intensive care and subsequent rehabilitation. A systematic ca…

Asphyxiaeducation.field_of_studybusiness.industryPopulationmedicine.diseaseSystemic inflammatory response syndromeEpilepsyAnesthesiaIntensive careHeart failureEmergency MedicineMedicineEpileptic seizuremedicine.symptombusinesseducationIntracranial pressureEuropean Journal of Emergency Medicine
researchProduct

Comparison of primary angioplasty with conservative therapy in patients with acute myocardial infarction and contraindications for thrombolytic thera…

1999

The benefit of primary angioplasty in patients with acute myocardial infarction (AMI) and contraindications for thrombolysis compared to a conservative regimen is still unclear. Out of 5,869 patients with AMI registered by the MITRA trial, 337 (5.7%) patients had at least one strong contraindication for thrombolytic therapy. Out of these 337 patients 46 (13.6%) were treated with primary angioplasty and 276 (86.4%) were treated conservatively. Patients treated conservatively were older (70 years vs. 60 years; P = 0.001), had a higher rate of a history with chronic heart failure (14.8% vs. 4.4%; P = 0.053), a higher heart rate at admission (86 beats/min vs. 74 beats/min; P = 0.001), and a hig…

Aspirinmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentGeneral MedicineThrombolysismedicine.diseaseRegimenInternal medicineDiabetes mellitusHeart failureHeart ratemedicineCardiologyRadiology Nuclear Medicine and imagingMyocardial infarctionCardiology and Cardiovascular MedicinebusinessContraindicationmedicine.drugCatheterization and Cardiovascular Interventions
researchProduct

Can Ventricular Resynchronization Reduce Atrial Fibrillation Recurrences?

2003

In recent years a new pacing therapy has been proposed for patients affected by heart failure (HF) in order to reduce inter- [1,2], intra- [3,4], and atrioventricular [5] (AV) dyssynchrony. Cardiac resynchronization therapy (CRT) has the goal of correcting these hemodynamic disorders, thus improving left ventricular (LV) performance. The benefits of CRT have been evaluated in a series of clinical trials [6-10].

Atrial pacemedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCardiac resynchronization therapyHemodynamicsAtrial fibrillationmedicine.diseaseSick sinus syndromeClinical trialHeart failureInternal medicinecardiovascular systemmedicineCardiologycardiovascular diseasesbusiness
researchProduct

Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide.

2020

Obesity has reached epidemic proportions in the United States and in much of the westernized world, contributing to considerable morbidity. Several of these obesity-related morbidities are associated with greater risk for death with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 penetrates human cells through direct binding with angiotensin-converting enzyme 2 receptors on the cell surface. Angiotensin-converting enzyme 2 expression in adipose tissue is higher than that in lung tissue, which means that adipose tissue may be vulnerable to COVID-19 infection. Obese patients also have worse outcomes with COVID-19 infection, including respiratory failure, n…

BMI body mass indexmedicine.medical_treatmentAdipose tissue030204 cardiovascular system & hematologyCHD coronary heart diseaseHF heart failureUS United States0302 clinical medicineRAAS renin-angiotensin-aldosterone systemPandemicMedicine030212 general & internal medicineCDC Centers for Disease Control and PreventionCOVID-19 coronavirus disease 2019TNF tumor necrosis factorHFpEF HF with preserved ejection fractionCV cardiovascularGeneral MedicinePrognosisICU intensive care unitPA physical activityMetS metabolic syndromePAH pulmonary arterial hypertensionCoronavirus Infectionsmedicine.medical_specialtyAF atrial fibrillationACE angiotensin-converting enzymePneumonia ViralCVD cardiovascular diseaseSARS-CoV-2 severe acute respiratory syndrome coronavirus 2ArticleSeverity03 medical and health sciencesBetacoronavirusInternal medicineIPF idiopathic pulmonary fibrosisHumansObesityMortalityHTN hypertension or hypertensivePandemicsMechanical ventilationAng II angiotensin IIbusiness.industrySARS-CoV-2CKD chronic kidney diseaseCOVID-19T2DM type 2 diabetes mellitusmedicine.diseaseAngiotensin IIObesityIL interleukinPneumoniaRespiratory failureMetabolic syndromebusinessSNS sympathetic nervousMayo Clinic proceedings
researchProduct

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Bisoprolol Fumarate

2014

Abstract Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate-release (IR) solid oral dosage forms containing bisoprolol as the sole active pharmaceutical ingredient (API) are reviewed. Bisoprolol is classified as a Class I API according to the current Biopharmaceutics Classification System (BCS). In addition to the BCS class, its therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions, and reported BE/bioavailability problems are taken into consideration. Qualitative compositions of IR tablet dosage forms of bisoprolol with a marketing authorization (MA) in ICH (Inter…

Bisoprolol FumarateCell Membrane PermeabilityAdrenergic beta-AntagonistsBiological AvailabilityPharmaceutical ScienceExcipientPharmacologyBioequivalenceDosage formBiopharmaceuticsExcipientsmedicineBisoprololHumansTissue DistributionBiotransformationChromatography High Pressure LiquidHeart FailureActive ingredientChemistryStereoisomerismHydrogen-Ion ConcentrationBiopharmaceutics Classification SystemBioavailabilityIntestinal AbsorptionSolubilityTherapeutic EquivalencyBisoprololmedicine.drugJournal of Pharmaceutical Sciences
researchProduct

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

2018

Diabetes mellitus is a chronic disease prevalence of which is high and continually growing. Cardiovascular disease continues to be the leading cause of death in patients with T2DM. The prevention of cardiovascular complications and the cardiovascular safety of treatments should be a primary objective when selecting treatment. Among all the drugs available, the compounds known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appear to be not just innocuous in terms of CVD but indeed to be beneficial. GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic control, dyslipidaemia, weight, or arterial hypertension but also might …

Blood GlucoseEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetesDiseaseReview Article030204 cardiovascular system & hematologyBioinformaticslcsh:Diseases of the endocrine glands. Clinical endocrinologyIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusmedicineHumansHypoglycemic AgentsCause of deathSistema cardiovascularlcsh:RC648-665DiabetisLiraglutidebusiness.industrySemaglutidemedicine.diseaseClinical trialDiabetes Mellitus Type 2Cardiovascular DiseasesHeart failureMalaltiesbusinessmedicine.drugJournal of Diabetes Research
researchProduct